Athira Pharma Inc. (ATHA) News

Athira Pharma Inc. (ATHA): $2.64

0.08 (+3.13%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add ATHA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#165 of 360

in industry

Filter ATHA News Items

ATHA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ATHA News Highlights

  • For ATHA, its 30 day story count is now at 3.
  • Over the past 21 days, the trend for ATHA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • ADD, BODY and DEC are the most mentioned tickers in articles about ATHA.

Latest ATHA News From Around the Web

Below are the latest news stories about ATHIRA PHARMA INC that investors may wish to consider to help them evaluate ATHA as an investment opportunity.

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | December 26, 2023

Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies

Exploratory findings add to increasing body of clinical and preclinical data supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative diseases Cognitive measures in the 40 mg dose group bolster confidence in ongoing Phase 2/3 LIFT-AD clinical trial of fosgonimeton in Alzheimer’s disease, which is on track to complete enrollment in early 2024 and report topline results in second half of 2024 BOTHELL, Wash., Dec. 12, 2023 (GLOBE NEWSWI

Yahoo | December 12, 2023

Sidoti Events, LLC's Virtual December Small-Cap Conference

NEW YORK, NY / ACCESSWIRE / December 5, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day December Small-Cap Conference taking place Wednesday and Thursday, December ...

Yahoo | December 5, 2023

Athira Pharma to Participate in Sidoti December Small Cap Investor Conference

Company Presentation to highlight novel therapeutic candidates targeting the HGF neurotrophic system in late-stage clinical development in neurodegenerative diseases, including Alzheimer’s diseaseBOTHELL, Wash., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the Sidoti Decemb

Yahoo | November 29, 2023

Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND

Presentation to highlight preclinical data from ATH-1105, Athira’s potential treatment candidate for amyotrophic lateral sclerosis (ALS)BOTHELL, Wash., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that a symposium presentation highlighting data from preclinical studies of ATH-1105 as a potential treatment candidate f

Yahoo | November 28, 2023

Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton’s Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer’s Disease

Data presented at Society for Neuroscience Annual Meeting 2023BOTHELL, Wash., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, presented new preclinical data supporting the potential therapeutic benefit of fosgonimeton for the treatment of Alzheimer’s disease (AD) and other neurodegenerative diseases at the Society for Neuroscience (SfN

Yahoo | November 15, 2023

Athira Pharma Insiders Placed Bullish Bets Worth US$556.3k

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...

Yahoo | November 15, 2023

Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates

Continues to report clinical and preclinical findings supporting the potential benefits of its small molecule therapeutic candidates targeting the neurotrophic HGF system as potential novel treatments for neurodegenerative diseases Expects to complete enrollment of Phase 2/3 LIFT-AD clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease patients by the first quarter of 2024 with topline data expected in second half 2024Maintains strong balance sheet to support innovative clinical

Yahoo | November 9, 2023

Athira Pharma to Participate in Jefferies London Healthcare Conference

BOTHELL, Wash., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate at the Jefferies London Healthcare Conference, taking place from November 14-16, 2023, in London. Details are as follows: Jefferies London Healthcare ConferenceFormat: Fireside Chat Date and Time: Thursday, November

Yahoo | November 8, 2023

Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

New results support the neuroprotective effects of ATH-1105 in preclinical models of ALS, as indicated by consistent reduction in plasma neurofilament light chain (NfL) levels and preservation of motor function Data presented at invitational Northeast ALS Consortium (NEALS) meeting BOTHELL, Wash., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodege

Yahoo | October 5, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!